Advaxis Doses First Patient in Phase 1/2 Head and Neck Cancer Study
January 21, 2014 at 07:35 AM EST
Advaxis, Inc., (NASDAQ: ADXS ) announced that the first patient has been dosed in a Phase 1/2 “window of opportunity” study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with
